Home
Search
Study Topics
Glossary
|
|
|
|
|
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date † | September 1, 2005 | ||||
Last Updated Date | March 1, 2007 | ||||
Start Date † | |||||
Current Primary Outcome Measures † |
IOP level in the study eye | ||||
Original Primary Outcome Measures † | Same as current | ||||
Change History | Complete list of historical versions of study NCT00143429 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures † |
Change in ocular safety assessments. Ocular and systemic adverse events throughout the study period | ||||
Original Secondary Outcome Measures † |
|
||||
Descriptive Information | |||||
Brief Title † | Corneal Versus Conjunctival Delivery Using a Delivery Device | ||||
Official Title † | Effect Of Corneal Versus Conjunctival Delivery On The Corneal Safety, Tolerability, and Antihypertensive Efficacy Of The Xalatan Ophthalmic Delivery Device | ||||
Brief Summary | Compare the antihypertensive efficacy of three methods for installing Xalatan |
||||
Detailed Description | |||||
Study Phase | Phase II | ||||
Study Type † | Interventional | ||||
Study Design † | Treatment, Randomized, Single Blind, Active Control, Crossover Assignment, Safety/Efficacy Study | ||||
Condition † |
|
||||
Intervention † | Drug: Xalatan | ||||
Study Arms / Comparison Groups | |||||
Publications * | |||||
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status † | Withdrawn | ||||
Enrollment † | 42 | ||||
Completion Date | |||||
Primary Completion Date | |||||
Eligibility Criteria † | Inclusion Criteria:
Exclusion Criteria:
|
||||
Gender | Both | ||||
Ages | 18 Years and older | ||||
Accepts Healthy Volunteers | No | ||||
Contacts †† | |||||
Location Countries † | |||||
Expanded Access Status | |||||
Administrative Information | |||||
NCT ID † | NCT00143429 | ||||
Responsible Party | |||||
Secondary IDs †† | |||||
Study Sponsor † | Pfizer | ||||
Collaborators †† | |||||
Investigators † |
|
||||
Information Provided By | Pfizer | ||||
Verification Date | October 2006 | ||||
† Required WHO trial registration data element. †† WHO trial registration data element that is required only if it exists. |